abstract |
The present invention relates to novel compounds useful in the treatment, amelioration or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of activation of inflammasome pathway components. In particular, the inflammasome pathway component is the NLRP3 inflammasome. More particularly, the compounds of the present invention have the ability to inhibit the NLRP3 inflammasome. Furthermore, the compounds of the present invention modulate, in particular reduce, IL-1β and/or IL-18 levels. |